Company News

Company News
September 11, 2023
Core One Labs Announces Non-Brokered Private Placement
Vancouver, British Columbia, Canada – September 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt:...
Read more
Company News
August 23, 2023
Core One Labs Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
Vancouver, British Columbia, Canada – August 23, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 04, 2023
Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease
Vancouver, British Columbia, Canada – August 4, 2023 – Core One Labs Inc. (CSE: COOL) (OTCQB: CLABF) (Frankfurt: LD6, WKN: A3CSSU), (the “Company”...
Read more
Company News
August 03, 2023
Core One Labs Applauds Groundbreaking Research on Psilocybin as a Potential Anorexia Treatment
Vancouver, British Columbia, Canada – August 3, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 01, 2023
Core One Labs’, Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One’s Wholly-Owned Subsidiary has filed a patent application with the United States Patent and Trademark Office Vancouver, British Columbia, Canada – August 1,...
Read more
Company News
July 28, 2023
Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Vancouver, British Columbia, Canada – July 28, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more